Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart FailureClinical Perspective by A. Rogier van der Velde, Lars Gullestad,

Slides:

Advertisements

Similar presentations

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Advertisements

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Cumulative Radiation Exposure and Cancer Risk Estimation in Children With Heart DiseaseCLINICAL PERSPECTIVE by Jason N. Johnson, Christoph P. Hornik, Jennifer.

Early Outcomes of Tricuspid Valve Replacement in Young Children by Heather L. Bartlett, Dianne L. Atkins, Trudy L. Burns, Kelly J. Engelkes, Sarah J. Powell,

Omega-3 Fatty Acid Blood Levels by H. Robert Superko, Scott M. Superko, Khurram Nasir, Arthur Agatston, and Brenda C. Garrett Circulation Volume 128(19):

Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei.

Hemoglobin levels and new-onset heart failure in the community

Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: An open-label, blinded end point, randomized.

Copyright © 2006 American Medical Association. All rights reserved.

Echocardiographic modalities for evaluation and risk stratification of heart failure patients. 3D indicates 3-dimensional; EF, ejection fraction; LA, left.

Figure 1 Study flow chart

Circ Cardiovasc Qual Outcomes

by Adam J. Singer, Robert H

Forecasting the Impact of Heart Failure in the United States

B-Type Natriuretic Peptide Testing and the Accuracy of Heart Failure Diagnosis in the Emergency DepartmentCLINICAL PERSPECTIVE by Amaali Lokuge, Louisa.

Early Evolution and Correlates of Urine Albumin Excretion in Patients Presenting With Acutely Decompensated Heart FailureClinical Perspective by Satoshi.

Atrial Fibrillation and Mortality in Heart FailureClinical Perspective

Arterioscler Thromb Vasc Biol

Association of Lipids With Incident Heart Failure Among Adults With and Without Diabetes MellitusClinical Perspective by Imo A. Ebong, David C. Goff, Carlos.

CYB561 mutations. CYB561 mutations. The upper part shows the structure of the CYB561 gene, with the positions of the identified mutations indicated. Gray.

Plasma Vitamin C, but Not Vitamin E, Is Associated With Reduced Risk of Heart Failure in Older MenClinical Perspective by Sasiwarang Goya Wannamethee,

Circ Cardiovasc Qual Outcomes

Association Between Mycoplasma Pneumonia and Increased Risk of Ischemic Stroke by Chia-Hung Chiang, Chin-Chou Huang, Wan-Leong Chan, Yu-Chun Chen, Tzeng-Ji.

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Site Selection and Performance in Clinical Trials

Modest Increase in Peak VO2 Is Related to Better Clinical Outcomes in Chronic Heart Failure PatientsClinical Perspective by Ann M. Swank, John Horton,

Physician and Patient Influences on Provider Performance

Plasma Free Fatty Acids and Risk of Heart FailureClinical Perspective

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Influence of Cardiac Surgeon Report Cards on Patient Referral by Cardiologists in New York State After 20 Years of Public Reporting by David L. Brown,

Contribution of Stroke to the Cochrane Stroke Group Trials Register

Effect of Provider Volume on the Accuracy of Hospital Report Cards

Circ Arrhythm Electrophysiol

Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes by Gunnar H. Gislason, Jeppe N. Rasmussen, Steen.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

by Parag C. Patel, Colby R. Ayers, Sabina A

Risk of Heart Failure Among Postmenopausal WomenCLINICAL PERSPECTIVE

Mathematical representation of Bayes theorem.

Circ Cardiovasc Qual Outcomes

Arterial Stiffness, Central Pressures, and Incident Hospitalized Heart Failure in the Chronic Renal Insufficiency Cohort StudyCLINICAL PERSPECTIVE by Julio.

Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic DysfunctionClinical Perspective.

Circ Cardiovasc Qual Outcomes

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Body Mass Index and Heart Failure Among Patients With Type 2 Diabetes MellitusCLINICAL PERSPECTIVE by Weiqin Li, Peter T. Katzmarzyk, Ronald Horswell,

Circ Cardiovasc Interv

Cancer in Young Adults With Ischemic Stroke

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Management of hypertension in patients with chronic kidney disease

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction Thor.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Baseline Characteristics by hs-CRP

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Marrick L. Kukin, MD Mayo Clinic Proceedings

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier analysis for the cumulative percentage of patients who remained hospitalized according to presence or absence of ARF with or without other.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

Adjusted cumulative incidence of stroke, by sex and heart failure status. Adjusted cumulative incidence of stroke, by sex and heart failure status. The.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Adjusted cumulative disability incidence by sex and heart failure status. Adjusted cumulative disability incidence by sex and heart failure status. The.

Presentation transcript:

Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart FailureClinical Perspective by A. Rogier van der Velde, Lars Gullestad, Thor Ueland, Pål Aukrust, Yu Guo, Aram Adourian, Pieter Muntendam, Dirk J. van Veldhuisen, and Rudolf A. de Boer Circ Heart Fail Volume 6(2):219-226 March 19, 2013 Copyright © American Heart Association, Inc. All rights reserved.

A, Cumulative incidence curves for mortality and HF hospitalization in Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) by categorical change between baseline and 3 months. A, Cumulative incidence curves for mortality and HF hospitalization in Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) by categorical change between baseline and 3 months. Log-rank P<0.001. B, Cumulative incidence curves for mortality and HF hospitalization in Coordinating Study Evaluating Outcomes of Advising and Counseling Failure (COACH) by categorical change between baseline and 6 months. Log-rank P<0.001. A. Rogier van der Velde et al. Circ Heart Fail. 2013;6:219-226 Copyright © American Heart Association, Inc. All rights reserved.

A, Cumulative incidence curves for cumulative mortality and HF hospitalization in Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) by galectin-3 percentage change from baseline, adjusted for baseline galectin-3 value. A, Cumulative incidence curves for cumulative mortality and HF hospitalization in Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) by galectin-3 percentage change from baseline, adjusted for baseline galectin-3 value. Log-rank P=0.005. B, Cumulative incidence curves for cumulative mortality and HF hospitalization in Coordinating Study Evaluating Outcomes of Advising and Counseling Failure (COACH) by galectin-3 percentage change from baseline, adjusted for baseline galectin-3 value. Log-rank P=0.029. A. Rogier van der Velde et al. Circ Heart Fail. 2013;6:219-226 Copyright © American Heart Association, Inc. All rights reserved.